Literature DB >> 35040751

In silico prediction of post-translational modifications in therapeutic antibodies.

Shabdita Vatsa1.   

Abstract

Monoclonal antibodies are susceptible to chemical and enzymatic modifications during manufacturing, storage, and shipping. Deamidation, isomerization, and oxidation can compromise the potency, efficacy, and safety of therapeutic antibodies. Recently, in silico tools have been used to identify liable residues and engineer antibodies with better chemical stability. Computational approaches for predicting deamidation, isomerization, oxidation, glycation, carbonylation, sulfation, and hydroxylation are reviewed here. Although liable motifs have been used to improve the chemical stability of antibodies, the accuracy of in silico predictions can be improved using machine learning and molecular dynamic simulations. In addition, there are opportunities to improve predictions for specific stress conditions, develop in silico prediction of novel modifications in antibodies, and predict the impact of modifications on physical stability and antigen-binding.

Entities:  

Keywords:  In silico prediction; chemical stability; developability; post-translational modifications; therapeutic antibody development

Mesh:

Substances:

Year:  2022        PMID: 35040751      PMCID: PMC8791605          DOI: 10.1080/19420862.2021.2023938

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  123 in total

1.  A new clustering of antibody CDR loop conformations.

Authors:  Benjamin North; Andreas Lehmann; Roland L Dunbrack
Journal:  J Mol Biol       Date:  2010-10-28       Impact factor: 5.469

2.  Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form.

Authors:  Pei Qi; David B Volkin; Hui Zhao; Michael L Nedved; Robert Hughes; Ryan Bass; Sun C Yi; Mark E Panek; Dana Wang; Paul Dalmonte; Michael D Bond
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

3.  Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody.

Authors:  Amanda K Miller; David M Hambly; Bruce A Kerwin; Michael J Treuheit; Himanshu S Gadgil
Journal:  J Pharm Sci       Date:  2011-02-01       Impact factor: 3.534

4.  Susceptibility of Antibody CDR Residues to Chemical Modifications Can Be Revealed Prior to Antibody Humanization and Aid in the Lead Selection Process.

Authors:  Ankai Xu; Hok Seon Kim; Samarkand Estee; Sharon ViaJar; William J Galush; Avinash Gill; Isidro Hötzel; Greg A Lazar; Paul McDonald; Nisana Andersen; Christoph Spiess
Journal:  Mol Pharm       Date:  2018-08-29       Impact factor: 4.939

Review 5.  A review of methods available to estimate solvent-accessible surface areas of soluble proteins in the folded and unfolded states.

Authors:  Syed Ausaf Ali; Md Imtaiyaz Hassan; Asimul Islam; Faizan Ahmad
Journal:  Curr Protein Pept Sci       Date:  2014       Impact factor: 3.272

6.  Prediction of the Hydrogen Peroxide-Induced Methionine Oxidation Propensity in Monoclonal Antibodies.

Authors:  Neeraj J Agrawal; Andrew Dykstra; Jane Yang; Hai Yue; Xichdao Nguyen; Carl Kolvenbach; Nicolas Angell
Journal:  J Pharm Sci       Date:  2018-01-08       Impact factor: 3.534

7.  Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody.

Authors:  Youngbin Baek; Nripen Singh; Abhiram Arunkumar; Andrew L Zydney
Journal:  Pharm Res       Date:  2016-12-29       Impact factor: 4.200

8.  Oxidation of methionine residues in aqueous solutions: free methionine and methionine in granulocyte colony-stimulating factor.

Authors:  Jhih-Wei Chu; Bernard R Brooks; Bernhardt L Trout
Journal:  J Am Chem Soc       Date:  2004-12-22       Impact factor: 15.419

9.  Role of surface exposed tryptophan as substrate generators for the antibody catalyzed water oxidation pathway.

Authors:  Alavattam Sreedhara; Kimberly Lau; Charlene Li; Brian Hosken; Frank Macchi; Dejin Zhan; Amy Shen; Daniel Steinmann; Christian Schöneich; Yvonne Lentz
Journal:  Mol Pharm       Date:  2012-11-26       Impact factor: 4.939

10.  Length-independent structural similarities enrich the antibody CDR canonical class model.

Authors:  Jaroslaw Nowak; Terry Baker; Guy Georges; Sebastian Kelm; Stefan Klostermann; Jiye Shi; Sudharsan Sridharan; Charlotte M Deane
Journal:  MAbs       Date:  2016 May-Jun       Impact factor: 5.857

View more
  3 in total

1.  Identification, Efficacy, and Stability Evaluation of Succinimide Modification With a High Abundance in the Framework Region of Golimumab.

Authors:  Tao Liu; Jin Xu; Qingcheng Guo; Dapeng Zhang; Jun Li; Weizhu Qian; Huaizu Guo; Xinli Zhou; Sheng Hou
Journal:  Front Chem       Date:  2022-04-05       Impact factor: 5.545

2.  Understanding the Stabilizing Effect of Histidine on mAb Aggregation: A Molecular Dynamics Study.

Authors:  Suman Saurabh; Cavan Kalonia; Zongyi Li; Peter Hollowell; Thomas Waigh; Peixun Li; John Webster; John M Seddon; Jian R Lu; Fernando Bresme
Journal:  Mol Pharm       Date:  2022-08-10       Impact factor: 5.364

Review 3.  Recent Advances and Future Directions in Downstream Processing of Therapeutic Antibodies.

Authors:  Allan Matte
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.